Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen

We prospectively studied clofarabine-fludarabine-busulfan (CloFluBu)-conditioning in allogeneic hematopoietic cell therapy (HCT) for lymphoid and myeloid malignancies and hypothesized that CloFluBu provides a less toxic alternative to conventional conditioning regimens, with adequate antileukemic ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Versluijs, A. Birgitta, de Koning, Coco C. H., Lankester, Arjan C., Nierkens, Stefan, Kollen, Wouter J., Bresters, Dorine, Lindemans, Caroline A., Boelens, Jaap Jan, Bierings, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941455/
https://www.ncbi.nlm.nih.gov/pubmed/34781362
http://dx.doi.org/10.1182/bloodadvances.2021005224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941455/
https://www.ncbi.nlm.nih.gov/pubmed/34781362
http://dx.doi.org/10.1182/bloodadvances.2021005224

Ejemplares similares